Dr. Rajeev Saggar, the Chief Medical Officer at Liquidia Corp (NASDAQ:LQDA), has completed a series of stock transactions totaling $709,816 between July 10 and July 13, 2026. These sales were executed at prices ranging from $71.39 to $71.52 per share. The stock has since appreciated to $76.47, marking a remarkable 427% return over the past year. According to InvestingPro analysis, the stock remains undervalued at current levels, appearing on the platform's Most Undervalued list despite its strong performance.
The transactions included the sale of 703 shares at $71.39 each and an additional 9,223 shares at $71.52 each, both occurring on July 13. These sales were conducted to cover taxes associated with the settlement of restricted stock units (RSUs) and performance stock units (PSUs) that were originally granted to Dr. Saggar on January 11, 2023, January 11, 2024, and January 11, 2025. The sales were carried out under a Rule 10b5-1 trading plan, which Dr. Saggar adopted on December 15, 2023.
Prior to these sales, on July 10, Dr. Saggar acquired 3,531 shares of Liquidia common stock and a further 4,487 shares. These shares were obtained through the conversion of Performance Stock Units (PSUs) on a one-for-one basis. The 3,531 shares originated from a PSU grant on January 11, 2024, of which 35,308 have vested to date. The 4,487 shares were from a PSU grant on January 11, 2025, with 26,918 having vested.
Following these reported transactions, Dr. Saggar directly holds 171,799 shares of Liquidia common stock. This total includes various unvested restricted stock units and shares acquired under the Liquidia Corporation 2020 Employee Stock Purchase Plan. InvestingPro subscribers have access to 18 additional ProTips for LQDA, including insights on the company's impressive 91.82% gross profit margin and profitability outlook, along with comprehensive Pro Research Reports available for over 1,400 US equities.
Liquidia Technologies Follow Analyze LQDA Included in our AI-picked strategies Review strategies 76.465 ▲+5.255(+7.38%) Closed·15:59:59·USD 75.50 ▼-0.990(-1.29%) After Hours·19:56:54 1D 1W 1M 6M 1Y 5Y Max Analyze LQDA
In other recent news, Liquidia Corporation has been making headlines with several significant developments. The company is set to join the S&P SmallCap 600 Index, effective before trading opens on June 22, 2026. This inclusion reflects Liquidia's compliance with market capitalization, liquidity, and profitability criteria set by S&P Dow Jones Indices.
On the legal front, H.C. Wainwright raised its price target for Liquidia to $75, maintaining a Buy rating, following a favorable Supreme Court ruling involving Hikma Pharmaceuticals and Amarin. Raymond James also reiterated a Strong Buy rating for Liquidia, citing positive implications from the same court decision.
In terms of stock ratings, BofA Securities downgraded Liquidia to Neutral from Buy, although it increased the price target to $79. The firm noted that the risk-reward profile has become more balanced after the stock's recent gains. Additionally, BofA raised its peak sales estimate for Liquidia's drug Yutrepia to $2.2 billion, following a successful launch that exceeded expectations. These recent developments underscore a dynamic period for Liquidia Corporation.